Asthma

• A Phase 2, Double-blind, Placebo-controlled, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma Recruitment ended
  2023-508039-29-00 4 2024-09-16 "Moderate-to-severe Asthma"
• Efficacy and safety of subcutaneous dupilumab in participants with asthma/asthmatic wheeze aged 2 to <6 years Recruitment ended
  2023-504331-41-00 5 2024-08-02 "Respiratory tract diseases - Wheezing, Asthma"
• A Study Evaluating the Efficacy and Safety of Povorcitinib (INCB054707) in Adults With Inadequately Controlled Moderate to Severe Asthma Recruitment ended
  2022-502570-16-01 4 2024-06-27 "Treatment of patients with inadequately controlled moderate "
• A Randomized, Double Blind, Active-Controlled Study on Efficacy and Safety of TEV-56248 in Patients with Asthma Recruitment ended
  2023-505435-12-00 5 2024-06-04
• Long-term safety and efficacy evaluation of subcutaneous amlitelimab in adult participants with moderate to severe asthma who completed trea … Recruitment ended
  2023-503385-24-00 4 2024-03-12
• A study to assess efficacy and safety of benralizumab in paediatric patients with severe eosinophilic asthma (severe asthma marked by high … Recruitment ended
  2022-501344-14-00 5 2023-06-05 "Paediatric Patients with Severe Eosinophilic Asthma Asthma i"
• Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients with Uncontrolled Moderate to Sev … Recruitment ended
  2024-513423-16-00 6 2022-08-25
• Predictive Signature of Benralizumab Response. BENRAPRED Study. Recruitment ended
  2024-514843-27-00 6 2021-10-11 "Severe asthma"
• A comparison study between adolescents with asthma and adults with asthma on how they absorb, metabolise and eliminate CHF 6001 Ended
  2024-516483-29-00 4 2025-03-24
• A Phase Ib, Multicentre, Randomised, Single-blind, Parallel-group, Placebo-controlled, Study to Characterise the Pharmacokinetics and Pharma … Ended
  2024-516474-30-00 3 2025-02-19
• A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AZD8630, Administered Once Daily via Inhalation, for 2 Weeks, in Adu … Ended
  2024-514213-35-00 3 2025-01-20
• A study to compare the pharmacokinetics of salbutamol administered via metered dose inhalers containing propellants HFA-152a (test) or HFA-1 … Ended
  2023-508279-36-00 3 2024-05-22 "Healthy volunteers"
• Safety and tolerability of single and multiple ascending doses of lunsekimig (SAR443765) in healthy participants Ended
  2023-509316-28-00 3 2024-05-06
• A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Selnoflast in Participants with Moderate to Severe Asthma Ended
  2023-504304-29-00 3 2024-03-01 "Moderate to Severe Asthma"
• A 12-week double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 p … Ended
  2023-503333-22-00 5 2024-01-15 "Moderate to severe controlled asthma according to Step 4 and"
• Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy Ended
  2022-502208-64-00 4 2023-11-25
• Bioequivalence study between two fluticasone propionate 500μg/salmeterol 50μg inhalation powders Ended
  2023-504789-48-00 2 2023-08-23 "Healthy volunteers: regular treatment of bronchial asthma, "
• A phase I study to evaluate an investigational medicinal product for the treatment of asthma, in healthy adult participants. Ended
  2023-504326-19-00 3 2023-08-03
• Bioequivalence study between two fluticasone propionate 250μg/salmeterol 50μg inhalation powders Ended
  2023-505198-34-00 2 2023-07-31 "Healthy volunteers.Regular treatment of bronchial asthma, wh"
• Study Evaluating the Effects of ARO-RAGE in Healthy Subjects and Patients with Inflammatory Lung Disease Ended
  2023-509654-60-00 9 2023-06-21 "Inflammatory Lung Disease"
• A Phase 1/2a Study Evaluating the Effects of ARO-MUC5AC Inhalation Solution in Healthy Subjects and Patients with Muco-Obstructive Lung Dise … Ended
  2024-514809-67-00 9 2023-06-21 "Asthma and Chronic obstructive pulmonary disease"
• A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twel … Ended
  2023-509243-27-00 4 2023-04-12 "Moderate-to-Severe Uncontrolled Asthma"
• Dose ranging study of amlitelimab in adult participants with moderate-to-severe asthma Ended
  2024-510641-33-00 4 2023-01-17
• Symptoms control and adhErenCe assessment during treatment with mepolizUmab new pREfilled devices. SECURE Ended
  2022-501029-19-00 6 2022-12-13

Showing 25–48 of 54 trials